Page 80 - Genentech News Today

The history of biotechnology shows how humans have been manipulating nature for our benefit for a long time—and how modern genetic engineering is

Editor's Note: In our recent white paper, Achieving Clinical Trial Diversity: Expanding Hospital Capacity to Offer Trials in the Community, Manatt Health discusses the important role of community...

Vacancy rates for office and research and development real estate continued to climb in San Mateo County to 18% last quarter, marking the sixth consecutive quarterly increase and a 7%

In Baxalta, Inc. v. Genentech, Inc., the Court of Appeals for the Federal Circuit upheld a summary judgment finding from the District of Delaware that claims 1-4, 19 and 20 of Baxaltas patent...

Welcome to our quarterly update relating to biologics and biosimilars, including post-grant and patent litigation challenges to blockbuster biologics. Since the enactment of the...

Pulmonary care clinicians may be habitually relying on outdated and inaccurate race-specific reference values when evaluating respiratory impairment in persons of African and Hispanic/Latino ancestry.

Women experiencing menopause make up an ever-larger section of the workforce. But employers are not responding to their needs, or even talking about it.

- Total Revenues of $471.9 million, Cabozantinib Franchise U.S. Net Product Revenues of $426.5 million -- Conference Call and Webcast Today at 5:00 PM Eastern Time -ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter of 2023 and provided an update on...

In Baxalta, Inc. v. Genentech, Inc., the Court of Appeals for the Federal Circuit upheld a summary judgment finding from the District of Delaware (Judge Timothy B. Dyk) that claims 1-4,...

EXEL earnings call for the period ending September 30, 2023.